Clearly market sentiment towards ENTA has improved following the results of the Ph2 RSVHR trial in late September. ENTA has been volatile in the past during daily trading sessions, but today was unusual. Wide swings in price… in the absence of news, in a down market. The spread between bid and ask is widening, trade volume increasing… Looking for good news from the company.
The point that I was trying to make may have been a little muddled. The $70m from October extended the cash runway by about a year meaning that it would not go to any further RSV trials. The leap was that this means that they are close to an RSV deal with somebody else picking up the entire tab. Selling it outright for the right amount would be fine with me also.
Market Data 
Markets 
AI
